AL

AIMEE LEWIS

AVENUE SOLUTIONS · Washington, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
4
last 3 years
Filings
10
3 agencies contacted
Activity
filings by quarter
Works on

Background

Career
Washington, DC
2024 - present

Specific issues

H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024
Medicare/Medicaid · 2024 Q3
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)
Medicare/Medicaid · 2024 Q3
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023
Medicare/Medicaid · 2024 Q3
Telehealth extension; Issues related to site neutral payments; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act
Medicare/Medicaid · 2024 Q3
Telehealth extension; Issues related to site neutral payments; Issues related to healthcare transparency and consolidation; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764 / H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act
Medicare/Medicaid · 2024 Q2
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)
Medicare/Medicaid · 2024 Q2

Clients

2024 · 3 filings
$██,███ / qtrUnlock
$██,███ / qtrUnlock
$██,███ / qtrUnlock
$██,███ / qtrUnlock

Filing history

2024 Q3
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
Q3lda.gov →
2024 Q3
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC.
Q3lda.gov →
2024 Q3
KIDNEY CARE PARTNERS
Q3lda.gov →
2024 Q3
FRESENIUS MEDICAL CARE NORTH AMERICA
Q3lda.gov →
2024 Q2
KIDNEY CARE PARTNERS
Q2lda.gov →
2024 Q2
FRESENIUS MEDICAL CARE NORTH AMERICA
Q2lda.gov →
2024 Q2
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
Q2lda.gov →
2024 Q2
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC.
Q2lda.gov →
2024 Q1
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
Q1lda.gov →
2024 Q1
KIDNEY CARE PARTNERS
Q1lda.gov →
Showing recent filings · full history on lda.gov